The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction – baseline. failure.9 A trial of ivabradine involving patients well as for the fidelity of this report to the trial tricular systolic dysfunction (BEAUTIFUL). The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction.

Author: Vuramar Minris
Country: Kosovo
Language: English (Spanish)
Genre: Health and Food
Published (Last): 8 October 2015
Pages: 110
PDF File Size: 11.98 Mb
ePub File Size: 14.14 Mb
ISBN: 347-5-97778-823-3
Downloads: 19197
Price: Free* [*Free Regsitration Required]
Uploader: Mazuzahn

Heart rate reduction with beta blockers has been identified in clinical literature and trials as a contributor to better prognosis in patients with heart failure.

There were no statistically significant differences between the two groups for the primary endpoint.


This entry form currently does not support special characters. Don’t miss out Read your latest personalised notifications Ok, got it. Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality.

In a prespecified ivabradone of patients with heart rate of 70 bpm triial greater, ivabradine treatment did not affect the primary composite outcome hazard ratio 0. What is important to note is that most of these patients were already receiving the guidelines-recommended cardiovascular therapy: Median follow-up was 19 months IQR You are a close professional associate of any of the authors e.

We aimed to test whether lowering the heart rate with ivabradine reduces cardiovascular death and morbidity in patients with coronary artery disease and left-ventricular systolic dysfunction. The results of the much awaited BEAUTIFUL morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction trial have shown that coronary artery disease CAD patients with left ventricular dysfunction LVD and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients heart rate above 70 bpm treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.

Ivabradine did not affect the primary composite endpoint hazard ratio 1. Ivabradine specifically inhibits the I f current in the sinoatrial node to lower heart rate, without affecting other aspects of cardiac function. Ivabradine reduced heart rate by 6 bpm SE 0. Hence the results of BEAUTIFUL constitute a step further in the management of these coronary patients with heart rate above 70 bpm because, for the first time it has been shown that pure heart rate reduction with ivabradine further reduces coronary events even in patients receiving the current optimal cardiovascular therapy.


This study also confirms that ivabradine is safe and well tolerated and can be used with all routinely prescribed cardiovascular drugs. Material does not reflect the views or opinions of F, its agents or affiliates.

There was a problem providing the content you requested

Register Already registered with FPrime? You work at the same institute as any of the authors. The secondary endpoints were all-cause hospital admission, hospital admission for worsening heart failure, any cardiovascular hospital admission, or composite cardiovascular death, or hospital admission for worsening heart failure, or hospital admission for non-fatal myocardial infarction MI. In a prespecified subgroup of patients with heart rate of 70 bpm or greater, ivabradine treatment did not affect the primary composite outcome hazard ratio 0.

By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as described in our privacy policy and terms and conditions. You expect to receive, or in the past 4 years have received, shared grant support or other beutiful with any of the authors.

Powered By Decision Support in Medicine. Consider the following examples, but note that this is not an exhaustive list:.

Due to having a narrow therapeutic index window in heart failure, in contrast to ivabradine, digoxin requires close monitoring with regards to serum drug levels, renal function, and electrolytes. We analysed patients by intention to treat.


Don’t have an account? The primary endpoint was a composite of cardiovascular death, admission to hospital trisl acute myocardial infarction, and admission beeautiful hospital for new onset or worsening heart failure. Reduction in heart rate with ivabradine does not improve cardiac outcomes in all patients with stable coronary artery disease and left-ventricular systolic dysfunction, but could be used to reduce the incidence of coronary artery disease outcomes in a subgroup of patients who have heart rates of 70 bpm or greater.


This Agreement shall begin on the date hereof. The use of certain tools provided by this website is subject to additional Terms and Conditions. Digoxin may also be used in concomitant atrial fibrillation, whereas ivabradine cannot.

Classified as close Confirmation 1. You are an Editor for the journal in which the article is published. The mean heart rate in these patients was 71 bpm and half of the patients had a heart rate more than 70 bpm. Ivabradine reduced heart rate by 6 bpm SE 0. A summary of the content will be automatically included. With the BEAUTIFUL results, ivabradine is the first antianginal treatment shown to reduce myocardial infarction and revascularisation and to have a good tolerability profile even when used with other drugs.

F reserves the right to monitor all Ivxbradine and to remove any Material which it considers in its absolute discretion to be unlawful, inappropriate, offensive or otherwise in breach of these Terms and Conditions. In the overall study population treatment with ivabradine did not result in a significant reduction of the primary composite end point Cardiovascular death, admission to hospital for acute MI and admission to hospital for heart failure.

With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Tr

Please disclose any competing interests that might be construed to influence your judgment of the validity or importance of the article, or any recommendation or review. The efficacy of ivabradine in heart failure patients is demonstrated via a randomized, multi-center, double-blind, placebo-controlled, parallel-group trial – SHIFT – which was published in To reduce the burden of cardiovascular disease. Certain parts of this website offer the opportunity for users to post opinions, information and material including without limitation academic papers and data ‘Material’ in areas of the website.

Ivabradine crosses the cell membrane and interacts within the pore loop from the intracellular side.